1.Bulletin of the Chemical Society of Japan, Volume 26, Pages 119-122, Journal, 1953 2.Dalton Transactions 2017,vol. 46, # 5, p. 1510 - 1519 3.Design and evaluation of ophthalmic pharmaceutical products. In Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 4th edn. New York Marcel Dekker, 2002 415-478 4.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer 5.Journal of Photochemistry and Photobiology, B Biology, Volume 97, Issue 1, Pages 18-21, Journal, 2009 6.Journal of Photochemistry and Photobiology, B Biology, Volume 115, Pages 51-57, Journal; Online Computer File, 2012 7.Nair AD, Lach JL. The kinetics of degradation of chlorobutanol. J Am Pharm Assoc (Sci) 1959; 48 390-395. 8.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine 9.Plasma?renin?activity-guided strategy for the management of hypertension. 10.Stability of chlorobutanol in aqueous solutions Journal of the American Pharmaceutical Association (1961), Volume 6, Issue 7, July 1966, Pages 372-373 11.Talanta, Volume 146, Pages 732-736, Journal; Online Computer File, 2016   [更多]

1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

提供 PDF電子版本 24小時(shí)內(nèi)提供 EP 版本包括（Calcium gluconate 和 calcium gluconate for injection）   [更多]

①文獻(xiàn)和網(wǎng)站來(lái)源必須權(quán)威、專業(yè)，盡量找外文或官網(wǎng)的文獻(xiàn)或報(bào)道，不能是百度百科等； ②簡(jiǎn)要概述的語(yǔ)句具有邏輯性和連貫性。 ③由于藥物本身存在信息不全或難找到信息源，以及藥物概述質(zhì)量不定（如翻譯質(zhì)量不定等）的情況，賞金酌情給出，請(qǐng)諒解。 ④單價(jià)8元/條，質(zhì)量偏低需折價(jià)計(jì)算。 58條合格，7條內(nèi)容偏少，58*8+7*4=492 注：此任務(wù)金額為不含稅金額，按照國(guó)家稅務(wù)相關(guān)法律法規(guī)，提現(xiàn)時(shí)個(gè)稅由藥智匯代扣代繳   [更多]

DrugsoftheFuture（DOF）2021年7-9期 文獻(xiàn)必須完整、準(zhǔn)確（備注：此任務(wù)已線下聯(lián)系好）   [更多]

1564元 ，合格說(shuō)明書(shū)賞金領(lǐng)取 請(qǐng)合格者在下方投稿   [更多]

求購(gòu)鹽酸異丙嗪注射液物報(bào)告   [更多]

詳細(xì)要求： 需求名稱：求購(gòu)雌二醇片藥品信息 具體要求：求購(gòu)全文 要求時(shí)間：近期 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會(huì)每天過(guò)來(lái)看的，謝謝各位藥智的戰(zhàn)友們   [更多]

①文獻(xiàn)和網(wǎng)站來(lái)源必須權(quán)威、專業(yè)，盡量找外文或官網(wǎng)的文獻(xiàn)或報(bào)道，不能是百度百科等；②簡(jiǎn)要概述的語(yǔ)句具有邏輯性和連貫性。 ③由于藥物本身存在信息不全或難找到信息源，以及藥物概述質(zhì)量不定（如翻譯質(zhì)量不定等）的情況，賞金酌情給出，請(qǐng)諒解。 ④單價(jià)8元/條，質(zhì)量偏低需折價(jià)計(jì)算。 43個(gè)合格，19個(gè)內(nèi)容偏少，43*8+19*4=420*此任務(wù)金額為不含稅金額，按照國(guó)家稅務(wù)相關(guān)法律法規(guī)，提現(xiàn)時(shí)個(gè)稅由藥智匯代扣代繳   [更多]

①文獻(xiàn)和網(wǎng)站來(lái)源必須權(quán)威、專業(yè)，盡量找外文或官網(wǎng)的文獻(xiàn)或報(bào)道，不能是百度百科等；②簡(jiǎn)要概述的語(yǔ)句具有邏輯性和連貫性。 ③由于藥物本身存在信息不全或難找到信息源，以及藥物概述質(zhì)量不定（如翻譯質(zhì)量不定等）的情況，賞金酌情給出，請(qǐng)諒解。 ④單價(jià)8元/條，質(zhì)量偏低需折價(jià)計(jì)算。 123個(gè)合格，13個(gè)內(nèi)容偏少，123*8+13*4=1036*此任務(wù)金額為不含稅金額，按照國(guó)家稅務(wù)相關(guān)法律法規(guī)，提現(xiàn)時(shí)個(gè)稅由藥智匯代扣代繳   [更多]